REVIEW

1127 Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
Olaf Merkel, Frank Hamacher, Eveline Sifft, Lukas Kenner, and Richard Greil
for the European Research Initiative on Anaplastic Large Cell Lymphoma

THERAPEUTIC DISCOVERY

1137 Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells
Chunyu Zhang, Abdel G. Elkahloun, Hongling Liao, Shannon Delaney, Barbara Saber, Betsy Morrow, George C. Prendergast, M. Christine Hollander, Joell J. Gills, and Phillip A. Dennis

1149 Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous Signaling
Linda C. Hsi, Suman Kundu, Juan Palomo, Bo Xu, Ryan Ficco, Michael A. Vogelbaum, and Martha K. Cathcart

1161 Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy
Ashutosh Shrivastava, Paula M. Kuzontkoski, Jerome E. Groopman, and Anil Prasad

PRECLINICAL DEVELOPMENT

1173 Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents
Qingbei Zhang, Vytas Bindokas, Jikun Shen, Hanli Fan, Robert M. Hoffman, and H. Rosie Xing
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1241</td>
<td>Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins</td>
<td>Arvi Yadav, Bhavna Kumar, Theodoros N. Teknos, and Pawan Kumar</td>
</tr>
<tr>
<td>1252</td>
<td>Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo</td>
<td>Ryuta Yamazaki, Yukiko Nishiyama, Tomio Furuta, Hiroshi Hatano, Yoshiaki Igarashi, Naoyuki Asakawa, Hiroshi Kodaira, Hiroyuki Takahashi, Ritsuo Aiyama, Takeshi Matsuzaki, Nao Yagi, and Yoshikazu Sugimoto</td>
</tr>
<tr>
<td>1264</td>
<td>Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1</td>
<td>Chong Zhang, Tian-yu Cai, Hong Zhu, Liu-qing Yang, Hai Jiang, Xiao-yu Dong, Yong-zhou Hu, Neng-ming Lin, Qiao-jun He, and Bo Yang</td>
</tr>
<tr>
<td>1276</td>
<td>Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells</td>
<td>Hong Zhou, John W. Marks, Walter N. Hittelman, Hideo Yagita, Lawrence H. Cheung, Michael G. Rosenblum, and Jeffrey A. Winkles</td>
</tr>
<tr>
<td>1289</td>
<td>Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer</td>
<td>Raquel De Souza, Payam Zahedi, Rose M. Badame, Christine Allen, and Michelene Piquette-Miller</td>
</tr>
<tr>
<td>1300</td>
<td>Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity</td>
<td>Siqing Fu, Aung Naing, Stacy L. Moulder, Kirk S. Culotta, David C. Madoff, Chaan S. Ng, Timothy L. Madden, Gerald S. Falchook, David S. Hong, and Razelle Kurzrock</td>
</tr>
</tbody>
</table>

**About the Cover**

A novel TRIM family member TRIM59 has proto-oncogenic activity in a transgenic mouse prostate cancer modeling test. Restricted TRIM59 gene expression in the mouse prostate using a prostate tissue-specific gene (PSP94) revealed the full potential for tumorigenesis and developed poorly differentiated cancer of the prostate and comedocarcinoma, which had features of neuroendocrine (small cell carcinoma) and central necrosis. The PSP94-TRIM59 mice coincided with the upregulation of genes specific to the Ras signaling pathway and bridging genes for SV40Tag-mediated oncogenesis. For details, see the article by Valiyeva and colleagues on page 1229.
Molecular Cancer Therapeutics

10 (7)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/10/7

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.